Patents by Inventor Peter Emtage

Peter Emtage has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250213708
    Abstract: Provided herein are chimeric transmembrane proteins, nucleic acids encoding these chimeric transmembrane proteins, and mammalian cells containing these nucleic acids, and methods of making and using these mammalian cells.
    Type: Application
    Filed: March 18, 2025
    Publication date: July 3, 2025
    Inventors: Peter EMTAGE, Rosa VINCENT
  • Patent number: 12297243
    Abstract: The present invention relates to methods and compositions for reducing the immunogenicity of chimeric Notch receptors, and specifically to transcription factors useful for controlling gene expression delivered to tissues by such chimeric Notch receptors.
    Type: Grant
    Filed: April 8, 2022
    Date of Patent: May 13, 2025
    Assignee: Cell Design Labs, Inc.
    Inventors: Peter Emtage, Amy E. Gilbert, Anselm Levskaya, Spencer Scott, Vladimir Anatolievich Slepushkin
  • Patent number: 12280119
    Abstract: Provided herein are chimeric transmembrane proteins, nucleic acids encoding these chimeric transmembrane proteins, and mammalian cells containing these nucleic acids, and methods of making and using these mammalian cells.
    Type: Grant
    Filed: March 21, 2019
    Date of Patent: April 22, 2025
    Assignee: KITE PHARMA, INC.
    Inventors: Peter Emtage, Rosa Vincent
  • Publication number: 20250109182
    Abstract: Provided herein are engineered receptors that include an extracellular domain (ECD) from a TGF-? receptor, a transmembrane domain (TMD), and that lack amino acid residues for signaling and phosphorylation, where such receptors are involved in cytokine signaling, for modulating TGF-? signaling, for methods of modulating TGF-? signaling, and for treating cancer using chimeric antigen receptors.
    Type: Application
    Filed: September 5, 2024
    Publication date: April 3, 2025
    Inventors: Sarah WYMAN, Peter EMTAGE, Gabrielle ROMAIN
  • Patent number: 12180517
    Abstract: Disclosed herein are polynucleotides encoding cell tags for use in immunotherapeutic applications, and systems comprising polynucleotide cell tags for regulating the activity of a cell. The compositions, methods and systems described herein provide tools for regulating activity of genetically engineered cells in a subject.
    Type: Grant
    Filed: June 11, 2021
    Date of Patent: December 31, 2024
    Assignee: PRECIGEN, INC.
    Inventors: Rutul Shah, Peter Emtage, Ramya Yarlagadda
  • Patent number: 12109235
    Abstract: Provided herein are engineered receptors involved in cytokine signaling. Also provided herein are engineered receptors for modulating TGF-? signaling, methods of modulating TGF-? signaling and treating cancer using chimeric antigen receptors.
    Type: Grant
    Filed: June 19, 2020
    Date of Patent: October 8, 2024
    Assignee: Kite Pharma, Inc.
    Inventors: Sarah Wyman, Peter Emtage, Gabrielle Romain
  • Patent number: 12065498
    Abstract: Provided herein are chimeric antigen receptors that binds specifically to B-cell maturation antigen (BCMA) and CD307e, nucleic acids that encode these chimeric antigen receptors, and methods of making and using these chimeric antigen receptors.
    Type: Grant
    Filed: September 27, 2018
    Date of Patent: August 20, 2024
    Assignee: Cell Design Labs, Inc.
    Inventors: Peter Emtage, Stephen Santoro, Stephanie Secrest
  • Patent number: 12060585
    Abstract: Disclosed herein are polynucleotides encoding cell tags for use in immunotherapeutic applications, and systems comprising polynucleotide cell tags for regulating the activity of a cell. The compositions, methods and systems described herein provide tools for regulating activity of genetically engineered cells in a subject.
    Type: Grant
    Filed: May 5, 2021
    Date of Patent: August 13, 2024
    Assignee: PRECIGEN, INC.
    Inventors: Rutul Shah, Peter Emtage, Ramya Yarlagadda
  • Publication number: 20240254188
    Abstract: Provided herein are chimeric antigen receptors (CARs) for cancer therapy, and more particularly, CARs containing a scFv from a CD33 monoclonal antibody. Provided are immune effector cells containing such CARs, and methods of treating proliferative disorders such as acute myeloid leukemia (AML), and relapsed or refractory AML.
    Type: Application
    Filed: September 6, 2023
    Publication date: August 1, 2024
    Applicant: PRECIGEN, INC.
    Inventors: Rutul SHAH, Tim CHAN, Peter EMTAGE, Ramya YARLAGADDA
  • Patent number: 11993660
    Abstract: Methods and compositions are provided for reversibly localizing proteins to the exterior part of the cell surface. Compositions provided herein can include nucleic acids that encode polypeptides of interest and the ligand binding domain (LBD) of a nuclear hormone receptor. Medical applications are provided, including controlling the toxicity of CAR T cells.
    Type: Grant
    Filed: August 13, 2021
    Date of Patent: May 28, 2024
    Assignee: CELL DESIGN LABS, INC.
    Inventors: Stephen Santoro, Scott Coyle, Levi Rupp, Peter Emtage
  • Publication number: 20230416339
    Abstract: Provided herein are chimeric transmembrane proteins and proteins, nucleic acids encoding these chimeric transmembrane proteins or proteins, and mammalian cells containing these nucleic acids, and methods of making and using these mammalian cells.
    Type: Application
    Filed: June 1, 2023
    Publication date: December 28, 2023
    Inventors: Peter Emtage, Gabrielle Romain, Rosa Vincent, Sarah Wyman
  • Patent number: 11787848
    Abstract: Provided herein are chimeric antigen receptors (CARs) for cancer therapy, and more particularly, CARs containing a scFv from a CD33 monoclonal antibody. Provided are immune effector cells containing such CARs, and methods of treating proliferative disorders such as acute myeloid leukemia (AML), and relapsed or refractory AML.
    Type: Grant
    Filed: June 7, 2017
    Date of Patent: October 17, 2023
    Assignee: PRECIGEN, INC.
    Inventors: Rutul Shah, Tim Chan, Peter Emtage, Ramya Yarlagadda
  • Patent number: 11708401
    Abstract: Provided herein are chimeric transmembrane proteins and proteins, nucleic acids encoding these chimeric transmembrane proteins or proteins, and mammalian cells containing these nucleic acids, and methods of making and using these mammalian cells.
    Type: Grant
    Filed: June 21, 2019
    Date of Patent: July 25, 2023
    Assignee: Kite Pharma, Inc.
    Inventors: Peter Emtage, Gabrielle Romain, Rosa Vincent, Sarah Wyman
  • Publication number: 20220372090
    Abstract: The present invention relates to methods and compositions for reducing the immunogenicity of chimeric Notch receptors, and specifically to transcription factors useful for controlling gene expression delivered to tissues by such chimeric Notch receptors.
    Type: Application
    Filed: April 8, 2022
    Publication date: November 24, 2022
    Inventors: Peter Emtage, Amy E. Gilbert, Anselm Levskaya, Spencer Scott, Vladimir Anatolievich Slepushkin
  • Publication number: 20220363728
    Abstract: The present invention relates to methods and compositions for reducing the immunogenicity of chimeric Notch receptors, and specifically to transcription factors useful for controlling gene expression delivered to tissues by such chimeric Notch receptors.
    Type: Application
    Filed: April 8, 2022
    Publication date: November 17, 2022
    Inventors: Peter Emtage, Amy E. Gilbert, Anselm Levskaya, Spencer Scott, Vladimir Slepushkin
  • Patent number: 11325957
    Abstract: The present invention relates to methods and compositions for reducing the immunogenicity of chimeric Notch receptors, and specifically to transcription factors useful for controlling gene expression delivered to tissues by such chimeric Notch receptors.
    Type: Grant
    Filed: June 18, 2018
    Date of Patent: May 10, 2022
    Assignee: Cell Design Labs, Inc.
    Inventors: Amy Gilbert, Vladimir Slepushkin, Peter Emtage, Anselm Levskaya, Spencer Scott
  • Publication number: 20220064609
    Abstract: Disclosed herein are polynucleotides encoding cell tags for use in immunotherapeutic applications, and systems comprising polynucleotide cell tags for regulating the activity of a cell. The compositions, methods and systems described herein provide tools for regulating activity of genetically engineered cells in a subject.
    Type: Application
    Filed: June 11, 2021
    Publication date: March 3, 2022
    Applicant: PRECIGEN, INC.
    Inventors: Rutul SHAH, Peter EMTAGE, Ramya YARLAGADDA
  • Publication number: 20220047677
    Abstract: The present disclosure relates to the field of cell therapy, and more specifically, to improving CAR and/or TCR function through improvement of the tumor microenvironment via improvement in cytokine signaling.
    Type: Application
    Filed: August 12, 2021
    Publication date: February 17, 2022
    Inventors: Peter Emtage, Jun Feng, Heba Nowyhed, Tammy Phung
  • Publication number: 20210395386
    Abstract: Methods and compositions are provided for reversibly localizing proteins to the exterior part of the cell surface. Compositions provided herein can include nucleic acids that encode polypeptides of interest and the ligand binding domain (LBD) of a nuclear hormone receptor. Medical applications are provided, including controlling the toxicity of CAR T cells.
    Type: Application
    Filed: August 13, 2021
    Publication date: December 23, 2021
    Inventors: Stephen Santoro, Scott Coyle, Levi Rupp, Peter Emtage
  • Publication number: 20210324350
    Abstract: Disclosed herein are polynucleotides encoding cell tags for use in immunotherapeutic applications, and systems comprising polynucleotide cell tags for regulating the activity of a cell. The compositions, methods and systems described herein provide tools for regulating activity of genetically engineered cells in a subject.
    Type: Application
    Filed: May 5, 2021
    Publication date: October 21, 2021
    Applicant: PRECIGEN, INC.
    Inventors: Rutul SHAH, Peter EMTAGE, Ramya YARLAGADDA